A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding
Launched by AMICUS THERAPEUTICS · Jan 30, 2020
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the experiences of women with Fabry disease who are pregnant or breastfeeding, along with their infants. Specifically, the study looks at how these women and their babies are affected by a treatment called migalastat, which some of them may be using. The goal is to gather valuable information on pregnancy and breastfeeding outcomes in this unique group of women.
To participate in this study, women must be diagnosed with Fabry disease and currently be pregnant or breastfeeding, regardless of whether they are taking migalastat. There are no specific exclusions, meaning most women with these conditions can join. Participants will be asked to share their experiences and health information during the study. This research is important as it aims to better understand the effects of Fabry disease and its treatment on both mothers and their infants, helping to improve care for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- Female patients meeting the following criteria will be eligible for study enrollment:
- • 1. Patients with Fabry disease who are pregnant and/or breastfeeding, whether or not they are exposed to migalastat
- • 2. Able and willing to provide informed consent or assent, if applicable.
- • 3. Able and willing to provide HCP contact information.
- Exclusion Criteria:
- • None
About Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare and orphan diseases, particularly those caused by genetic mutations. With a focus on lysosomal storage disorders, Amicus leverages advanced protein engineering and gene therapy approaches to create treatment options that address unmet medical needs. Committed to patient-centric research, the company collaborates with healthcare professionals and patient advocacy groups to ensure that its clinical trials are designed to deliver meaningful outcomes. Through its robust pipeline and dedication to scientific excellence, Amicus Therapeutics aims to enhance the quality of life for individuals affected by these complex conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials